Unique ID issued by UMIN | UMIN000043140 |
---|---|
Receipt number | R000049242 |
Scientific Title | Collaborative study on longitudinal tau accumulation of [18F]PM-PBB3 ([18F]APN-1607) in patients with Parkinson's disease-related disorders |
Date of disclosure of the study information | 2021/02/01 |
Last modified on | 2023/07/31 18:19:41 |
Collaborative study on longitudinal tau accumulation of [18F]PM-PBB3 ([18F]APN-1607) in patients with Parkinson's disease-related disorders
Longitudinal collaborative study with [18F]PM-PBB3 ([18F]APN-1607)
Collaborative study on longitudinal tau accumulation of [18F]PM-PBB3 ([18F]APN-1607) in patients with Parkinson's disease-related disorders
Longitudinal collaborative study with [18F]PM-PBB3 ([18F]APN-1607)
Japan | Asia(except Japan) | North America |
Parkinson's disease-relatd disorders (progressive supranuclear palsy spectrum, parkinson's disease)
Neurology | Psychiatry | Adult |
Others
NO
The purpose of this study is to quantitatively evaluate the distribution of tau protein lesions in the brain and to understand their changes over time in order to explore the pathological basis of the disease and its clinical manifestations.
Efficacy
Relationship between [18F]PM-PBB3([18F]APN-1607) PET changes over time and clinical symptoms
Observational
20 | years-old | <= |
Not applicable |
Male and Female
<Cross-sectional study>
Healthy volunteers who have participated in the following existing studies conducted by QST since February 2017, and who have undergone testing by December 31, 2019.
1) Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3 (Research Protocol No. 16-036)
2) Tau PET imaging in patients with schizophrenia and patients with frontotemporal dementia (No. 16-037)
3) PET study of central PDE10A density and tau deposition in bipolar disorder. (No. 17-027)
<Longitudinal study>
Healthy volunteers, patients with Parkinson's disease, and patients with progressive supranuclear palsy spectrum among the study subjects who participated in the following existing studies conducted at QST after November 2017.
Mapping of brain tau deposition in tauopathy by PET with [18F]PM-PBB3 (No. 17-034)
(1) Cases in which the research subject or his/her representative refuses the secondary use of data for other research when the existing research is explained.
(2) Cases in which the research subject or his/her representative refuses the use of the data for this research at the time the data is shared with the collaborating research organization.
(3) Cases in which there is missing data that may affect data analysis.
59
1st name | Hironobu |
Middle name | |
Last name | Endo |
National Institutes for Quantum Science and Technology
Department of Functional Brain Imaging
263-8555
4-9-1, Anagawa, Inage-ku, Chiba-shi, Chiba, Japan
0432063249
endo.hironobu@qst.go.jp
1st name | Shizuko |
Middle name | |
Last name | Kawakami |
National Institutes for Quantum and Radiological Science and Technology
Clinical Research Support Section
263-8555
4-9-1, Anagawa, Inage-ku, Chiba-shi, Chiba, Japan
81432064713
kawakami.shizuko@qst.go.jp
National Institutes for Quantum Science and Technology
Biogen MA Inc
Outside Japan
Biogen MA Inc
APRINOIA Therapeutics Inc
Certified Review Board
4-9-1, Anagawa, Inage-ku, Chiba-shi, Chiba, Japan
81432064706
helsinki@qst.go.jp
NO
2021 | Year | 02 | Month | 01 | Day |
Published
59
Completed
2020 | Year | 12 | Month | 23 | Day |
2021 | Year | 01 | Month | 27 | Day |
2021 | Year | 02 | Month | 01 | Day |
2023 | Year | 03 | Month | 31 | Day |
<Cross-sectional study>
Healthy volunteers who have participated in the following existing studies conducted by QST since February 2017, and who have undergone testing by December 31, 2019.
1) Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3 (Research Protocol No. 16-036)
2) Tau PET imaging in patients with schizophrenia and patients with frontotemporal dementia (No. 16-037)
3) PET study of central PDE10A density and tau deposition in bipolar disorder. (No. 17-027)
<Longitudinal study>
Healthy volunteers, patients with Parkinson's disease, and patients with progressive supranuclear palsy spectrum among the study subjects who participated in the following existing studies conducted at QST after November 2017.
Mapping of brain tau deposition in tauopathy by PET with [18F]PM-PBB3 (No. 17-034)
2021 | Year | 01 | Month | 26 | Day |
2023 | Year | 07 | Month | 31 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049242
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |